Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Inovio Pharmaceuticals & U.S. Army Receive $3.5 Million Biodefense Grant

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Inovio to advance painless device to simultaneously deliver multiple vaccines using electroporation technology.

Inovio Pharmaceuticals, Inc. has been selected to receive a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of its next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation. Inovio is collaborating with Dr. Connie Schmaljohn, Chief Scientist at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The goal of this public/private partnership is to develop a device that would facilitate rapid vaccination of U.S. troops stationed around the world against multiple infectious diseases and protect civilian populations from pandemic threats.

Dr. J. Joseph Kim, Inovio's president & CEO, said, "This new device would provide a means to rapidly and painlessly deliver multiple vaccines simultaneously to large groups of people. This collaboration builds on Inovio's strong relationship with Dr. Schmaljohn and her team at USAMRIID in which Inovio is bringing medical innovation to several biodefense efforts. Moreover, the advancements from this project will enable rapid and efficient delivery of Inovio's SynCon® vaccines for universal flu, HIV, and other infectious diseases on a mass scale."

The Inovio team of researchers has been collaborating with USAMRIID scientists to advance a DNA vaccine for the Lassa virus, which the DOD has designated as a "Category A" pathogen. In previous testing, an optimized DNA vaccine for the Lassa virus delivered by surface electroporation demonstrated complete protection against a virus challenge in both guinea pig and non-human primate disease models. Although prior results are highly encouraging and electroporation delivery is very tolerable from a patient perspective, improvements are still needed to make the technology more suitable for multiple vaccine administrations and mass vaccinations.

This NIAID grant builds on a 2011 Small Business Innovation Research Grant in which Inovio demonstrated a delivery device that was designed to deliver two separate DNA vaccines simultaneously. In this new program, Inovio will develop the multi-vaccine electroporation delivery device to address biodefense vaccine targets – notably to advance the Lassa virus vaccine through to clinical studies.

The research effort will investigate the novel simultaneous delivery of multiple DNA vaccines — final testing will use the Lassa virus and other arenaviruses — at distinct spatial sites while avoiding immune interference between vaccines. In addition, this new device platform could significantly increase the dose of vaccine delivered at one time which is a current limitation in vaccine delivery to the skin. The new skin surface device resulting from this research will leverage Inovio's latest surface DNA vaccine delivery technology, based on the company's proprietary electroporation delivery platform which uses millisecond electrical pulses to dramatically improve cellular uptake of the vaccine and resulting immune responses. Inovio vaccines delivered with electroporation devices for cancer and infectious diseases have previously demonstrated best in class T-cell and antibody responses in clinical studies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Inovio Pharmaceutical's DNA Vaccine for the MERS Virus Induces Robust Immune Response
No vaccine exists for the MERS virus that has killed 42% of those infected.
Monday, December 02, 2013
Inovio Pharmaceuticals' Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
Mice and monkey study demonstrates robust and broad immune responses.
Thursday, July 25, 2013
PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals Partner
Follow-on agreement will lead to clinical trials.
Wednesday, January 09, 2013
Inovio Pharmaceuticals CMV Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
No vaccine or cure exists for virus that can be life threatening to infants, immune compromised, and transplant patients.
Wednesday, November 28, 2012
Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!